Latest Findings in Diagnosis and Treatment of Gynecological Malignancies—Volume II

Dear Colleagues,

Gynecological cancers still represent one of the leading causes of female death around the world. Nevertheless, the mortality and morbidity of these diseases have been on a downward trend in recent years, thanks to technological advances in surgery, oncology, and palliative care.

This Special Issue was created with the intention of collecting the latest findings in the scientific field that may refine a clinical practice or clarify the “grey areas” still present in the scientific literature. This Special Issue comes in the light of major and groundbreaking scientific discoveries that have revolutionized the approach to major gynecologic oncologic diseases, such as the LACC trial by Ramirez, which questioned the appropriateness of minimally invasive approaches in the surgical treatment of cervical carcinoma, or the SOLO-1 Trial, which introduced the use of PARP-Inhibitors for the treatment of ovarian carcinomas, opening up new scenarios still to be explored today. In addition, the increasing spread of robotic surgery, as well as the refinement of laparoscopic instruments, offer new technical horizons previously difficult to imagine. Further, the growing knowledge regarding the molecular signature of gynecological cancer and radio diagnostic advantages offers physicians the opportunity to diagnose and treat gynecological cancer early and personalize treatment. Finally, a not insignificant aspect in the management of gynecologic oncology patients is the important scientific progress that has occurred with the application of ERAS protocols and the optimization of palliative care. The scientific community is experiencing a very prosperous period that is resulting in a steady improvement in clinical care. Our Special Issue was created to collect the latest findings in these areas. We, therefore, invite our authors to contribute their most important testimonials in the form of case reports, original articles, review articles, and meta-analyses.

Dr. Stefano Cianci
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gynecologic oncology
• gynecological surgery
• cancer treatment
• cancer diagnosis

• Latest Findings in Diagnosis and Treatment of Gynecological Malignancies in Medicina